Sarcoma, Soft TissueNCT02309242
Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study
A study testing Neuropsychological assessment, MRI in people with Sarcoma, Soft Tissue and Osteosarcoma Tumor, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
Trial summary
The aim of the proposed project is to study the long-term impact of adjuvant systemic multi- agent chemotherapy (cisplatin, anthracyclines, vincristine, methotrexate, alkylating agents) in survivors (treated between 1992 and 2014 in UZ Leuven) of paediatric bone or soft tissue sarcomas on neurocognitive functioning. Read more about this study
- Who is it for?
- Ages 7 to 25 years
- Conditions the study is for
- Sarcoma, Soft Tissue, Osteosarcoma Tumor
- What is being tested?
- Neuropsychological assessment, MRI
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteBelgium
- Study dates
- Dec 2014to Oct 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Survivors of paediatric bone or soft tissue sarcomas, who were treated from 1992 onwards in the paediatric haematooncology department of UZLeuven according to one of the following treatment protocols.
- For soft tissue sarcomas: MMT 95, MMT 98, RMS2005 or NRST2005
- For Ewing sarcoma: EICESS 92, Euro-Ewing 99 or Euro-Ewing 2008
- For osteosarcoma: EORTC 80931 or Euramos1 protocols
- There will be variability in treatment regimens, but the patient group will be clustered into four subgroups:
- Cisplatin and anthracyclines
Show all 9Show fewer
- Cisplatin, anthracyclines and methotrexate
- Alkylating agents
- Alkylating agents and anthracyclines
Who cannot join
- Mental retardation documented before treatment
- Inability to perform the tests because of motor or sensory deficits
- Epilepsy
- Other cognitive disorders
- Depression
- Relapse
Show all 10Show fewer
- Parameningeal or intracranial sarcomas
- Syndrome (e.g. Down)
- Autologous stemcell transplantation
- Head/neck/spinal radiotherapy or psychopharmaca
Trial locations and contacts
1 site in 1 country.
Belgium1 site, 1 recruiting
- Recruiting
UZ Leuven , pediatric oncology
Leuven, Vl Brabant, 3000
Anne Uyttebroeck, MD, PhD, +32 16 343972, anne.uyttebroeck@uzleuven.be
Charlotte Sleurs, Msc, +32 16 340650, charlotte.sleurs@uzleuven.be
About this study
The aim of the proposed project is to study the long-term impact of adjuvant systemic multi- agent chemotherapy (cisplatin, anthracyclines, vincristine, methotrexate, alkylating agents) in survivors (treated between 1992 and 2014 in UZ Leuven) of paediatric bone or soft tissue sarcomas on neurocognitive functioning.
Read the detailed description
The aim of the proposed project is to study the long-term impact of adjuvant systemic multi- agent chemotherapy (cisplatin, anthracyclines, vincristine, methotrexate, alkylating agents) in survivors (treated between 1992 and 2014 in UZ Leuven) of paediatric bone or soft tissue sarcomas on neurocognitive functioning using neuropsychological testing in combination with advanced Magnetic Resonance (MR) imaging techniques in a cross-sectional design. The majority of studies focus on either neuropsychological outcomes or structural imaging. In this project we want to combine both methodologies. MR will mainly focus on microstructural changes in white matter and differences in brain connectivity, while with our neuropsychological tests we will assess a broad range of cognitive functioning. From the obtained MR parameters and neuropsychological test results, the proposed study wants to answer the following research questions:
- Are there subtle differences in neurocognitive function and behavior related to chemotherapy exposure for survivors of paediatric bone or soft tissue sarcomas?
- Are there differences in morphological/functional MR parameters that could relate to subtle cognitive differences in cognitive functioning after chemotherapy exposure? Can we detect structural treatment-induced WM injury? Can we see differences in brain neural activity/connectivity during rest between the groups?
- Is there a correlation between the obtained morphological/functional MR parameters and neuropsychological test results?
- Is there a correlation between the possible difference in white matter microstructure and gender, age at diagnosis and the duration of treatment?
To answer these questions, we will implement the following measurements:
- From the computerized Amsterdam Neuropsychological Tasks (ANT) system we will test simple motor reaction time, sustained, focused and divided attention, inhibitory control and cognitive flexibility and motor coordination.
- Specific verbal-auditory memory and nonverbal, visual-spatial memory functioning will be registered by the Children's Memory Scale (CMS) for subjects younger than 16 years and with the auditory verbal learning test and the Rey visual design learning test for the subjects older than 16 years. Age-adjusted standardized norms are available for each test.
- The BRIEF (Behavior Rating Inventory of Executive Function) explores executive functioning in school (5-17 years), work (+18 years) and home (5-17 years and +18 years) environments.
- The assessment of intellectual functioning consists of the Wechsler Intelligence Scale for Children (WISC-III) for patients between 6 and 16 years and the Wechsler Adult Intelligence (WAIS-III) for adolescents aged 17 years or older.
- Quality of life will be investigated by the PEDSQL generic version for young adults .
- The Achenbach questionnaires (Child Behavior Checklist, Teacher Report Form, Youth Self Report Form, Adult Behavior Checklist, Adult Self Report Form) items for internalizing, externalizing, and total problems will be filled out by the parents, teacher or relatives and patients themselves.
- All participants will complete the Spielberger State-Trait Anxiety Inventory and the Beck Depression Inventory-II.
Currently, the neurocognitive follow-up of paediatric bone and brain tumour patients (NKP21/22c, National Cancer Plan Onkelinx) as well as children with congenital heart disease (IWT-TBM, 3M110068) or treated in a paediatric intensive care unit is also based on this test battery. All these tests and questionnaires have been extensively described and used to quantify neurocognitive development and Quality of life in various paediatric populations. The testing will be performed at least one year after the end of treatment.
MRI imaging to study the neural substrate of possible neurotoxic effects of chemotherapy-treatment Advanced MR neuroimaging techniques in combination with the detailed cognitive and behavioral assessment will be used. All subjects will be imaged on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. Neuroimaging consists of 3D T1-weighted FLAIR and advanced diffusion weighted- imaging (DWI), to examine white matter (WM) microstructure, and resting state functional MRI (rfMRI) to visualize neuronal activity of the brain at rest (examination with eyes closed).
- DWI - a technique enabling the visualization and characterization of the WM architecture via the self-diffusion of water molecules - allows us to study potential chemotherapy-induced changes in the WM microstructure. Damage to WM structures - for example axonal loss or demyelination - may change quantitative DWI parameters such as fractional anisotropy (FA), mean diffusivity (MD) and diffusion kurtosis.
- rfMRI uses the vascular response nearby electrically active neurons to indirectly visualize brain activity and allows us to determine the connectivity between the different brain regions at rest.
The duration of the proposed scan protocol is maximum 45 minutes.
Statistical analyses Neuropsychological performance Performance on neurocognitive measures of the survivors will be compared with an age-matched control group using ANOVA and simple contrasts with controls as reference and STAI and BDI scores as covariates. Partial eta squared (hp2) will be computed to estimate effect sizes (weak effect: ηp²≈0.03; moderate: ηp²≈0.06; large: ηp²≥0.14). Cohen's d will be used for simple contrasts (small effect: 0.2 < d < 0.3; medium: 0.3 < d < 0.8; large: d> 0.8). Subsequent analyses are conducted only on those neurocognitive measures where survivors demonstrated significantly lower values than the age-matched control group. The independent effects of the predictors (treatment group, gender, age at treatment, duration of treatment and socioeconomic status) on these neuropsychological score will be analyzed with a repeated measures mixed effects regression model.
Imaging State of the art image analysis approaches are applied to process and analyze the acquired brain images and to document differences in structural white matter or resting state brain activity between the study groups. DTI images will be processed and analyzed using explore DTI, in-house developed software and voxel-based statistical analysis. Furthermore, performance on neurocognitive measures and differences in FA and MD maps of the survivors will be compared with an age and sex-matched control group using ANOVA and simple contrasts with controls as reference and STAI and BDI scores as covariates. Seed-based analysis and independent component analysis (ICA) will be applied to analyze the resting state fMRI data. The association between the obtained MRI parameters and the performance on neurocognitive tests will be investigated using (voxel-based) correlation analysis. The independent effects of the predictors (treatment group, gender, age at treatment, duration of treatment and socioeconomic status) on these neuropsychological and imaging scores will be analyzed with a repeated measures mixed effects regression model.
Sample size and power Study subjects are recruited from the paediatric haemato-oncology center in UZLeuven. We expect to recruit 30 patients within the time frame of this project. A healthy control group (n=30) matched for age and gender will be included. Demographic characteristics such as social economic, school and work status are assessed.
It is difficult to perform a fundamental power calculation, because little is known about the impact of the chemotherapy in bone or soft tissue sarcomas on cognitive functioning so far. We expect to recruit 30 survivors of bone or soft tissue sarcoma in childhood. If we take these numbers into account and based on a previous studies reporting white matter FA changes and cognitive changes in childhood ALL patients who received chemotherapy, we would have a power of 98.54% to detect a difference of 1 standard deviation on cognitive tasks (1-tailed, α=0.05). For white matter FA changes, we would have a power of 98%.
- Conditions
- Sarcoma, Soft Tissue, Osteosarcoma Tumor
- Being tested
- Neuropsychological assessment, MRI
- Medical subject headings
- Sarcoma, Osteosarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuropsychological assessment, MRIBehavioural
All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
| Study group | Role | What they receive |
|---|---|---|
| Neuropsychological assessment, MRI | No intervention | This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex. Receives: Behavioral: Neuropsychological assessment, MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neuropsychological functioning
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2014 (estimated)
- Study startDec 2014
- Primary completionOct 2018 (estimated)
- Study completionOct 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcoma, Soft TissueStudies of the same condition, open and under way.
- More trials run by Universitaire Ziekenhuizen KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anne Uyttebroeck, MD, PhD, Principal investigator, UZ Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02309242
- Sponsor's protocol ID
- S57349
- Status last verified
- Aug 2015
- First submitted
- 24 Oct 2014
- Last updated
- 21 Aug 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study
- ClinicalTrials.gov ID
- NCT02309242
- Acronym / sponsor ID
- S57349
- Conditions
- Sarcoma, Soft Tissue, Osteosarcoma Tumor
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenUniversity, hospital or other
- Study start
- Dec 2014
- Primary completion
- Oct 2018 (estimated)
- Study completion
- Oct 2018 (estimated)
- First posted
- 5 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the proposed project is to study the long-term impact of adjuvant systemic multi- agent chemotherapy (cisplatin, anthracyclines, vincristine, methotrexate, alkylating agents) in survivors (treated between 1992 and 2014 in UZ Leuven) of paediatric bone or soft tissue sarcomas on neurocognitive functioning.
Detailed description
The aim of the proposed project is to study the long-term impact of adjuvant systemic multi- agent chemotherapy (cisplatin, anthracyclines, vincristine, methotrexate, alkylating agents) in survivors (treated between 1992 and 2014 in UZ Leuven) of paediatric bone or soft tissue sarcomas on neurocognitive functioning using neuropsychological testing in combination with advanced Magnetic Resonance (MR) imaging techniques in a cross-sectional design. The majority of studies focus on either neuropsychological outcomes or structural imaging. In this project we want to combine both methodologies. MR will mainly focus on microstructural changes in white matter and differences in brain connectivity, while with our neuropsychological tests we will assess a broad range of cognitive functioning. From the obtained MR parameters and neuropsychological test results, the proposed study wants to answer the following research questions:
- Are there subtle differences in neurocognitive function and behavior related to chemotherapy exposure for survivors of paediatric bone or soft tissue sarcomas?
- Are there differences in morphological/functional MR parameters that could relate to subtle cognitive differences in cognitive functioning after chemotherapy exposure? Can we detect structural treatment-induced WM injury? Can we see differences in brain neural activity/connectivity during rest between the groups?
- Is there a correlation between the obtained morphological/functional MR parameters and neuropsychological test results?
- Is there a correlation between the possible difference in white matter microstructure and gender, age at diagnosis and the duration of treatment?
To answer these questions, we will implement the following measurements:
- From the computerized Amsterdam Neuropsychological Tasks (ANT) system we will test simple motor reaction time, sustained, focused and divided attention, inhibitory control and cognitive flexibility and motor coordination.
- Specific verbal-auditory memory and nonverbal, visual-spatial memory functioning will be registered by the Children's Memory Scale (CMS) for subjects younger than 16 years and with the auditory verbal learning test and the Rey visual design learning test for the subjects older than 16 years. Age-adjusted standardized norms are available for each test.
- The BRIEF (Behavior Rating Inventory of Executive Function) explores executive functioning in school (5-17 years), work (+18 years) and home (5-17 years and +18 years) environments.
- The assessment of intellectual functioning consists of the Wechsler Intelligence Scale for Children (WISC-III) for patients between 6 and 16 years and the Wechsler Adult Intelligence (WAIS-III) for adolescents aged 17 years or older.
- Quality of life will be investigated by the PEDSQL generic version for young adults .
- The Achenbach questionnaires (Child Behavior Checklist, Teacher Report Form, Youth Self Report Form, Adult Behavior Checklist, Adult Self Report Form) items for internalizing, externalizing, and total problems will be filled out by the parents, teacher or relatives and patients themselves.
- All participants will complete the Spielberger State-Trait Anxiety Inventory and the Beck Depression Inventory-II.
Currently, the neurocognitive follow-up of paediatric bone and brain tumour patients (NKP21/22c, National Cancer Plan Onkelinx) as well as children with congenital heart disease (IWT-TBM, 3M110068) or treated in a paediatric intensive care unit is also based on this test battery. All these tests and questionnaires have been extensively described and used to quantify neurocognitive development and Quality of life in various paediatric populations. The testing will be performed at least one year after the end of treatment.
MRI imaging to study the neural substrate of possible neurotoxic effects of chemotherapy-treatment Advanced MR neuroimaging techniques in combination with the detailed cognitive and behavioral assessment will be used. All subjects will be imaged on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. Neuroimaging consists of 3D T1-weighted FLAIR and advanced diffusion weighted- imaging (DWI), to examine white matter (WM) microstructure, and resting state functional MRI (rfMRI) to visualize neuronal activity of the brain at rest (examination with eyes closed).
- DWI - a technique enabling the visualization and characterization of the WM architecture via the self-diffusion of water molecules - allows us to study potential chemotherapy-induced changes in the WM microstructure. Damage to WM structures - for example axonal loss or demyelination - may change quantitative DWI parameters such as fractional anisotropy (FA), mean diffusivity (MD) and diffusion kurtosis.
- rfMRI uses the vascular response nearby electrically active neurons to indirectly visualize brain activity and allows us to determine the connectivity between the different brain regions at rest.
The duration of the proposed scan protocol is maximum 45 minutes.
Statistical analyses Neuropsychological performance Performance on neurocognitive measures of the survivors will be compared with an age-matched control group using ANOVA and simple contrasts with controls as reference and STAI and BDI scores as covariates. Partial eta squared (hp2) will be computed to estimate effect sizes (weak effect: ηp²≈0.03; moderate: ηp²≈0.06; large: ηp²≥0.14). Cohen's d will be used for simple contrasts (small effect: 0.2 < d < 0.3; medium: 0.3 < d < 0.8; large: d> 0.8). Subsequent analyses are conducted only on those neurocognitive measures where survivors demonstrated significantly lower values than the age-matched control group. The independent effects of the predictors (treatment group, gender, age at treatment, duration of treatment and socioeconomic status) on these neuropsychological score will be analyzed with a repeated measures mixed effects regression model.
Imaging State of the art image analysis approaches are applied to process and analyze the acquired brain images and to document differences in structural white matter or resting state brain activity between the study groups. DTI images will be processed and analyzed using explore DTI, in-house developed software and voxel-based statistical analysis. Furthermore, performance on neurocognitive measures and differences in FA and MD maps of the survivors will be compared with an age and sex-matched control group using ANOVA and simple contrasts with controls as reference and STAI and BDI scores as covariates. Seed-based analysis and independent component analysis (ICA) will be applied to analyze the resting state fMRI data. The association between the obtained MRI parameters and the performance on neurocognitive tests will be investigated using (voxel-based) correlation analysis. The independent effects of the predictors (treatment group, gender, age at treatment, duration of treatment and socioeconomic status) on these neuropsychological and imaging scores will be analyzed with a repeated measures mixed effects regression model.
Sample size and power Study subjects are recruited from the paediatric haemato-oncology center in UZLeuven. We expect to recruit 30 patients within the time frame of this project. A healthy control group (n=30) matched for age and gender will be included. Demographic characteristics such as social economic, school and work status are assessed.
It is difficult to perform a fundamental power calculation, because little is known about the impact of the chemotherapy in bone or soft tissue sarcomas on cognitive functioning so far. We expect to recruit 30 survivors of bone or soft tissue sarcoma in childhood. If we take these numbers into account and based on a previous studies reporting white matter FA changes and cognitive changes in childhood ALL patients who received chemotherapy, we would have a power of 98.54% to detect a difference of 1 standard deviation on cognitive tasks (1-tailed, α=0.05). For white matter FA changes, we would have a power of 98%.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Neuropsychological assessment, MRI | No intervention | Behavioral: Neuropsychological assessment, MRIThis is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex. |
Who may qualify
- Ages
- 7 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (9 listed)
- Survivors of paediatric bone or soft tissue sarcomas, who were treated from 1992 onwards in the paediatric haematooncology department of UZLeuven according to one of the following treatment protocols.
- For soft tissue sarcomas: MMT 95, MMT 98, RMS2005 or NRST2005
- For Ewing sarcoma: EICESS 92, Euro-Ewing 99 or Euro-Ewing 2008
- For osteosarcoma: EORTC 80931 or Euramos1 protocols
- There will be variability in treatment regimens, but the patient group will be clustered into four subgroups:
Key exclusion criteria (10 listed)
- Mental retardation documented before treatment
- Inability to perform the tests because of motor or sensory deficits
- Epilepsy
- Other cognitive disorders
- Depression
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuropsychological assessment, MRIAll subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires | Behavioural | Neuropsychological assessment, MRI |
Primary outcome
Neuropsychological functioning
Time frame: 4 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2015.
Related trials for Sarcoma, Soft Tissue
RecruitingPhase 2
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
Soft Tissue Sarcoma
RecruitingPhase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Lymphoma, Waldenström Macroglobulinemia (WM)
Enrolling by invitationPhase 1
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
Soft Tissue Sarcoma, Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anne Uyttebroeck, MD, PhD principal investigator
UZ Leuven
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuropsychological assessment, MRI in people with Sarcoma, Soft Tissue and Osteosarcoma Tumor, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Anne Uyttebroeck, MD, PhD (+32 16 3439 ext. 72, anne.uyttebroeck@uzleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neuropsychological functioning (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2015.